Health Care

Inside Natera: Insider selling spiked by Sheena Jonathan, yet company fundamentals and positive sentiment keep the stock on an upward trajectory. Discover what this means for investors.

Charles River Laboratories insider trade shows disciplined Rule 10b5‑1 use—buy & sell on 21 Oct, no net change, but signals confidence in future R&D growth.

Insider CFO John Borgeson’s 10‑b5‑1 trades show disciplined, buy‑low‑sell‑high moves amid strong institutional buying, highlighting Kodiak Sciences’ long‑term strategy.

How Kaye Mark’s insider sales signal Elevance Health’s confidence and liquidity strategy amid rising shares and robust earnings.

WCAS XII’s 1.5‑million‑share divestiture of Innovage reveals how institutional investors value tech‑driven healthcare firms that drive value‑based reimbursement, scalable cloud platforms, and sustainable revenue, shaping future capital allocation an…

CEO’s 2,210‑share sale at $29.16 sparks debate—insider liquidity vs. confidence, amid rising insider buying and volatile stock price at Rapport Therapeutics.

MEDPACE insider buy: Exec. VP Susan Burwig snaps up 2,700 shares at $166.73, a discount to $654, signaling confidence in a growing, tech‑driven healthcare cash flow.

Agios insider sales reveal disciplined portfolio management, not a bearish signal—see how Gheuens’ 10b5‑1 trades align with pipeline progress and market sentiment.

Ignite Aggregator LP’s recent 1.5 M‑share sale of Innovage Holding at $9.25 signals a tactical divestiture near the stock’s 52‑week high, raising clues for investors on valuation, liquidity, and upcoming board actions.

Insider buys 3,600 Rapport shares, signaling confidence in its CNS pipeline amid market swings and a shift toward value‑based reimbursement. Discover the impact.